Clinical Trials Study
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Oct 28, 2024; 30(40): 4367-4375
Published online Oct 28, 2024. doi: 10.3748/wjg.v30.i40.4367
Inetetamab combined with S-1 and oxaliplatin as first-line treatment for human epidermal growth factor receptor 2-positive gastric cancer
Ying Kong, Qi Dong, Peng Jin, Ming-Yan Li, Li Ma, Qi-Jun Yi, Yu-E Miao, Hai-Yan Liu, Jian-Gang Liu
Ying Kong, Qi Dong, Peng Jin, Ming-Yan Li, Li Ma, Qi-Jun Yi, Yu-E Miao, Hai-Yan Liu, Department of Oncology, The Second Affiliated Hospital of Shandong First Medical University, Tai’an 271000, Shandong Province, China
Jian-Gang Liu, Department of Gastrointestinal Surgery, The Second Affiliated Hospital of Shandong First Medical University, Tai’an 271000, Shandong Province, China
Co-first authors: Ying Kong and Qi Dong.
Co-corresponding authors: Hai-Yan Liu and Jian-Gang Liu.
Author contributions: Kong Y and Dong Q designed the study and wrote the manuscript, they are co-first authors of this manuscript; Jin P, Li MY, and Ma L performed the experiments and acquired the data; Yi QJ and Miao YE analyzed the data and interpreted the data; Liu HY and Liu JG contributed to the drafting of the article and critical revision of the manuscript, they are co-corresponding authors of this manuscript; and all the authors read and approved the final manuscript.
Supported by China Scientific Research Fund for HER2 Target from China Anti-Cancer Association, No. CORP-239-M9.
Institutional review board statement: The study was approved by the Ethics Committee of the Second Affiliated Hospital of Shandong First Medical University (Ethics Approval Number: 2021-001).
Clinical trial registration statement: This study is registered at the China Clinical Trials Center website (http://www.chictr.org.cn). The registration identification number is ChiCTR2100051574.
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: The data used in the current study are available from the corresponding author upon reasonable request.
CONSORT 2010 statement: The authors have read the CONSORT 2010 Statement, and the manuscript was prepared and revised according to the CONSORT 2010 Statement.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Hai-Yan Liu, MD, Chief Physician, Professor, Department of Oncology, The Second Affiliated Hospital of Shandong First Medical University, No. 366 Taishan Street, Tai’an 271000, Shandong Province, China. liuhaiyan@sdfmu.edu.cn
Received: August 8, 2024
Revised: September 7, 2024
Accepted: September 23, 2024
Published online: October 28, 2024
Processing time: 68 Days and 21.9 Hours
Core Tip

Core Tip: Trastuzumab combined with the S-1 plus oxaliplatin (SOX) regimen is the standard first-line treatment for human epidermal growth factor receptor 2-positive advanced gastric cancer. This study demonstrated that the efficacy of inetetamab combined with the SOX regimen is similar to that of trastuzumab combined with the SOX regimen, and the inetetamab group exhibited superior progression-free survival without any additional adverse events.